Drug Trial Radar · NCT04715646
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
84
Actual
Start
Mar 11, 2021
Primary completion
Jul 8, 2030
Study completion Jul 8, 2030
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jan 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
Conditions
- Epilepsy
Interventions
BrivaracetamDrug
Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses. Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral Oral solution Concentration: 10 mg/ml Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) during the studyTime frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
- Incidence of treatment-emergent serious adverse events (SAEs) during the studyTime frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
- Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the studyTime frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
Ep0156 259
Hawthorne, New York
Ep0156 237
Durham, North Carolina
Ep0156 210
Budapest, Hungary
Ep0156 247
Budapest, Hungary
Ep0156 232
Miskolc, Hungary
Ep0156 230
Roma, Italy
Ep0156 803
Bunkyō City, Japan
Ep0156 808
Chūō, Japan
Ep0156 800
Gifu, Japan
Ep0156 807
Hiroshima, Japan
Ep0156 815
Kodaira-shi, Japan
Ep0156 813
Kōshi, Japan
Ep0156 806
Kyoto, Japan
Ep0156 811
Nagoya, Japan
Ep0156 812
Niigata, Japan
Ep0156 818
Ōbu, Japan
Ep0156 819
Ōmura, Japan
Ep0156 817
Osaka, Japan
Ep0156 805
Sapporo, Japan
Ep0156 816
Sendai, Japan
Ep0156 809
Shimotsuke, Japan
Ep0156 814
Shizuoka, Japan
Ep0156 804
Tokyo, Japan
Ep0156 810
Yokohama, Japan
Ep0156 802
Yonago, Japan
Ep0156 223
Aguascalientes, Mexico
Ep0156 609
Culiacán, Mexico
Ep0156 603
Guadalajara, Mexico
Ep0156 406
Kielce, Poland
Ep0156 402
Krakow, Poland
Ep0156 401
Poznan, Poland
Ep0156 248
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.